Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

X4 Pharmaceuticals Q3 2026 Results: Net Loss of $20.2M, Loss Narrows

X4 Pharmaceuticals reported total revenue of $14.4 million for the first nine months of 2026, a decrease from $32.5 million in the prior year period, primarily due to lower license revenue. Net product revenue from XOLREMDI grew to $7.6 million year-to-date, while the company reduced its nine-month operating loss to $56.7 million through significant cuts in research, development, and administrative expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.91.8
Profit before tax-20.2-29.8
Net income-20.2-29.8
EPS (diluted, $ a share)$-0.16$-0.69

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+63.1%
Source

10-Q filed with the SEC, NASDAQ: XFOR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

X4 Pharmaceuticals, Inc: key numbers

Share price
$2.83Close, Nov 16
Market cap
$289M
Shares outstanding
102.11MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from X4 Pharmaceuticals, Inc

All →
10:00 AM ET 8-K
Investor Presentation

X4 Pharmaceuticals Investor Presentation

X4 Pharmaceuticals is hosting a Virtual Investor Day on October 29, 2026, to provide updates on its strategic business plans and clinical pipeline. The presentation focuses on the commercialization of mavorixafor for primary chronic neutropenia and the progress of the ongoing 4WARD Phase 3 clinical study.

4:06 PM ET Form 4
Insider Buying

X4 Pharmaceuticals Executive Chairman Adam R. Craig Buys $11.9K of Stock

Adam R. Craig, Executive Chairman, bought 4,600 shares of X4 Pharmaceuticals, Inc at $2.58 a share, worth $11.9K in total on Oct 16, 2026. Shares held after the trade: 333,251 (+1.4%).

Value
$11.9K
Shares
4,600
Price
$2.58
Role
Executive Chairman
Holding change
+1.4%
Trade date
Oct 16, 2026
5:23 PM ET 8-K
Loan & Debt

X4 Pharmaceuticals $150M Debt Financing with K2 HealthVentures LLC

X4 Pharmaceuticals entered into a $150 million senior secured term loan facility with K2 HealthVentures, consisting of an immediate $80 million tranche and an additional $70 million available upon request and lender approval. The proceeds were used to repay an existing $75 million loan from Hercules and will support the potential commercial launch of mavorixafor. The new facility features a 48-month maturity and an interest-only period through at least October 2029.

Value
$150M
Counterparty
K2 HealthVentures LLC
Term
4 years
4:03 PM ET Form 4
Insider Selling

X4 Pharmaceuticals CFO David Kirske Sells $33.7K of Stock

David Kirske, CFO, sold 11,767 shares of X4 Pharmaceuticals, Inc at $2.86 a share, worth $33.7K in total on Oct 1, 2026. Shares held after the trade: 155,983 (-7.0%).

Value
$33.7K
Shares
11,767
Price
$2.86
Role
CFO
Holding change
-7.0%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.